Lupus Foundation launches "Cut it Out" campaign

Is 14 days too long for people to abstain from coffee or movies out? Lupus advocates hope it will help others relate. 

By Judy Packer-Tursman • Nov. 2, 2016

Merck KGaA and ACS spotlight cancer in women

Better diagnosis and preventive measures could reduce cancer deaths in women.

By Suzanne Elvidge • Nov. 2, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Lilly feels the Bern over insulin pricing

Vermont Sen. Bernie Sanders took another swipe at the drug industry and its pricing strategies, this time targeting Eli Lilly and Novo Nordisk. 

By Lisa LaMotta • Nov. 2, 2016

Pfizer touts Ibrance's safety as competition intensifies

It's showdown time as Pfizer, Novartis and others try to corner a lucrative market.

By Judy Packer-Tursman • Nov. 2, 2016

Shire confident in hemophilia despite looming pricing challenge

As part of the Baxalta deal, Shire picked up a portfolio of hemophilia drugs, which it hopes to grow as a complement to its ADHD and genetic disease drugs.

By Ned Pagliarulo • Nov. 1, 2016

Amid pricing scrutiny, Amgen CEO predicts more value-based contracts

CEO Robert Bradway defended Amgen's pricing strategy last week, but said the biotech should not be rewarded if its drugs don't deliver a strong benefit.

By Ned Pagliarulo • Oct. 31, 2016

Celgene's Otezla grows, but still lags anti-TNF market

While the arthritis drug is picking up new patients, it has failed to steal patients from entrenched TNF inhibitors. 

By Lisa LaMotta • Oct. 27, 2016

FDA taking a closer look at DTC animation

But major players like Eli Lilly, AstraZeneca and Regeneron have some issues with the agency's proposal.

By Jacob Bell • Oct. 26, 2016

Amgen invests in Israeli digital health incubator

The incubator, which is backed by a multinational consortium, aims to invest in 40 new companies over eight years. 

By Joe Cantlupe • Oct. 26, 2016

Allergan puts Profiles in Focus with DTC campaign

Kybella's DTC campaign taps into people's worries about looking good in social media pics. 

By Suzanne Elvidge • Oct. 26, 2016

NCPA: FDA to blame for EpiPen price hikes

A report from the National Center for Policy Analysis pins the blame for price increases of the epinephrine auto-injector on federal regulators. 

By Joe Cantlupe • Oct. 26, 2016

Opportunistic Kaleo promises lower-cost EpiPen alternative

Amidst ongoing backlash over Mylan's pricing of EpiPen, Kaleo hopes to relaunch its beleaguered epinephrine autoinjector.

By Lisa LaMotta • Oct. 26, 2016

Humana to cover Sarepta's DMD drug with caveats

Coverage for the controversial treatment will require prior authorization.

By Ned Pagliarulo • Oct. 26, 2016

How pharma is using Twitter to connect with patients

Big pharma has a lot of constraints when it comes to social media, but their Twitter feeds can be very useful ... sometimes. 

By Lisa LaMotta • Oct. 26, 2016

Lilly says complete Sola failure unlikely

A looming readout from Lilly's Phase 3 trial of its Alzheimer's drug solanezumab will likely prove pivotal in shaping the near-term outlook for the drugmaker.

By Ned Pagliarulo • Oct. 25, 2016

BI tapping real-world data for Pradaxa

Boehringer Ingelheim’s reversal agent showed effectiveness in hospital and physician offices caring for AF patients, compared to the standard of care. 

By Joe Cantlupe • Oct. 24, 2016

Pfizer anchors inflammation hopes in Xeljanz

After a slow launch, the RA drug is picking up speed, leading the big pharma to invest in growing it further. 

By Lisa LaMotta • Oct. 19, 2016

Merck lays groundwork for biosimilar push

The New Jersey pharma launched a new educational website on biosimilars, hoping to boost awareness as it readies several candidates for the U.S. market. 

By Ned Pagliarulo • Oct. 19, 2016

Lilly expands global health efforts

With Lilly 30x30, the drugmaker plans to earmark $90 million over the next five years to improve access to diabetes, cancer and TB care. 

By Suzanne Elvidge • Oct. 19, 2016

CAR-T ready for flight, says Kite

In an investor day presentation, the cell therapy company outlined its strategy to lock in a first-to-market advantage in CAR-T. 

By Ned Pagliarulo • Oct. 19, 2016

Pfizer readies Inflectra launch

The Remicade copy will be only the second biosimilar available on the U.S. market. Yet Pfizer's planned discount may leave some hoping for more. 

By Lisa LaMotta • Oct. 17, 2016

Valeant: We're raising prices, but not much

After facing months of criticism and charges related to price gouging, Valeant is trying to be more transparent about its price increases. 

By Lisa LaMotta • Oct. 16, 2016

Insulin makers become casualties of pricing war

Novo Nordisk, Sanofi and Eli Lilly are facing off in the insulin market, battling for position as prices go down and competition heats up.

By Ned Pagliarulo • Oct. 13, 2016

Next stop in AstraZeneca fire sale: China

AstraZeneca agreed to sell off Chinese rights to two diabetes drugs in a deal with 3SBio, continuing an active stretch of out-licensing. 

By Joe Cantlupe • Oct. 13, 2016

Biocompatibles settles DOJ marketing probe

A subsidiary of London-based BTG, Biocompatibles reached a settlement with the U.S. Department of Justice over marketing of its interventional medicine brand. 

By Joe Cantlupe • Oct. 12, 2016